Arcus Biosciences (RCUS) Stock Looks Strong On Returns But Stretched On SalesSimplywall·17 hours agoRCUS+1.42%SMMT+3.22%
Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law FirmPR Newswire·1 day ago, 06:58 PMRCUS+1.42%
Arcus Biosciences, Inc. Stock 12‑Month Price Target Raised to $38.82, Implies 35% UpsideTradingView·Aug 14 at 02:20 AMRCUS+1.42%
Arcus Biosciences (RCUS) Reported Q2 2026 Results, Is The Stock A Bargain?Simplywall·Aug 13 at 10:34 AMRCUS+1.42%
Arcus Biosciences memberi hibah induksi: opsi 2.850 saham dan 1.450 RSU untuk karyawan baruPUBT·Aug 11 at 03:35 PMRCUS+1.42%
Arcus Biosciences | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 41 MEarnings Watch·Aug 5 at 10:07 PMRCUS+1.42%
Arcus Biosciences (RCUS) Expands Kidney Cancer Collaboration, Is The Stock Still Undervalued?Simplywall·Aug 3 at 10:22 AMRCUS+1.42%SMMT+3.22%
Arcus Biosciences, Inc. Stock 12‑Month Price Target Cut to $37.17, Implies 32% UpsideTradingView·Aug 3 at 09:20 AMRCUS+1.42%
Arcus Biosciences Announces New Employment Inducement Grants | RCUS Stock NewsStockTitan·Jul 27 at 07:35 AMRCUS+1.42%
Does Arcus Biosciences’ (RCUS) AVEO Tie-Up Hint At A New Combo-First RCC Strategy?Simplywall·Jul 24 at 12:02 PMRCUS+1.42%
Arcus Biosciences partners with AVEO Oncology to test casdatifan-tivozanib combo in kidney cancer studyPUBT·Jul 22 at 03:40 PMRCUS+1.42%
Arcus Biosciences, Summit Therapeutics team up to test casdatifan-ivonescimab combo in kidney cancerPUBT·Jul 22 at 03:40 PMSMMT+3.22%RCUS+1.42%
